Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2024 | Overweight | Cantor Fitzgerald | |
| 8/13/2024 | $18.00 → $22.00 | Outperform → Strong Buy | Raymond James |
| 8/12/2024 | $19.00 → $20.00 | Outperform | Leerink Partners |
| 7/25/2024 | $18.00 | Outperform | Raymond James |
| 3/5/2024 | $6.00 → $18.00 | Market Perform → Outperform | Leerink Partners |
| 2/20/2024 | Mkt Perform → Outperform | William Blair | |
| 9/20/2023 | Outperform → Mkt Perform | William Blair | |
| 1/31/2023 | $10.00 | Outperform | Wedbush |
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
Cantor Fitzgerald initiated coverage of ARS Pharmaceuticals with a rating of Overweight
Raymond James upgraded ARS Pharmaceuticals from Outperform to Strong Buy and set a new price target of $22.00 from $18.00 previously
Leerink Partners reiterated coverage of ARS Pharmaceuticals with a rating of Outperform and set a new price target of $20.00 from $19.00 previously
Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that Express Scripts, the pharmacy benefits business of Evernorth Health Services, has added neffy® (epinephrine nasal spray) to its Commercial national formularies. This decision makes neffy broadly available to millions of their commercially insured
Preliminary fourth quarter neffy® net product revenue of approximately $6.5 million Preliminary cash, cash equivalents and short-term investments of $314.0 million at year-end 2024 to support an operating runway of at least three years Company to present at 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 7:30am PT SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced preliminary, unaudited neffy® (epinephrine nasal spray) net product revenue
Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2 mg in other key global regions SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that ARS Pharma has filed for approval of neffy® (epinephrine nasal spray) 2 mg in Canada and the United Kingdom (U.K.), where it will be marketed as EURneffy®, on behalf of its licensing partner, ALK- Abelló A/S (ALK). neffy was recently ap
Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that Express Scripts, the pharmacy benefits business of Evernorth Health Services, has added neffy® (epinephrine nasal spray) to its Commercial national formularies. This decision makes neffy broadly available to millions of their commercially insured
SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
144 - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
144 - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (("ARS Pharma", NASDAQ:SPRY). The agreement grants ALK exclusive global rights to the neffy® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key elements in ALK's new strategy Allergy+ and supports ALK's long-term financial ambitions. Needle-free, nasal delivery of adrenaline has the potential to become an important treatment option in anaphylaxisALK also gains rights to future indications, including acute urticaria flares (in development)ALK to pay USD 145 million in up
neffy Offers Adults and Children (≥30 kg) Living with Severe Allergic Reactions the First New Delivery Method for Epinephrine in more than 35 Years Well-capitalized to Support Launch and Commercialization of neffy in the U.S., and an Expected Operating Runway of at Least Three Years ARS Pharma to Host Investor Conference Call on Monday, August 12, 2024, at 8:00 am ET SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced that the U.S. Food and Drug Administration (FDA)